Pulmonary arterial pressure (PAP)-flow coordinates were obtained in 14 anesthetized dogs before and after pulmonary hypertension was induced with autologous blood clots. Cardiac output (CO) was altered by systemic arteriovenous fistulas. The PAP-CO coordinates were always rectilinear. Before emboli, the mean vascular closing or outflow pressure (the pressure intercept of the PAP-CO line) was 8.8 2.1 (SD) mm Hg. Emboli increased PAP (15.1 + 1.6 to 36.5 + 3.5 mm Hg; p < .001) and decreased CO (3.8 + 0.6 to 2.4 + 0.8 liters min-'; p < .001). Incremental resistance (the slope of the PAP-CO line) only increased slightly. On the other hand, the marked increase in PAP was predominantly due to an increase in effective outflow pressure (from 8.8 + 2.1 to 28.6 ± 3.6; p < .001). Hydralazine was administered in a dose sufficient to double CO. This did not affect PAP and caused an inconsistent and small decrease in incremental resistance. However, a consistently significant decrease in effective outflow pressure, averaging 23%, was observed. In this canine preparation of pulmonary hypertension the predominant effect of hydralazine appears to be a decrease in the mean vascular closing or outflow pressure.
THE ACTION of vasoactive drugs in pulmonary hypertensive disorders has been the focus of extensive investigation. Several clinical reports'-' and a recent canine study4 have documented an increase in cardiac output (CO) and a decrease in pulmonary vascular resistance with hydralazine. In these studies, pulmonary vascular resistance, calculated as (mean pulmonary arterial pressure [PAP] -left atrial pressure) + CO is assumed to reflect the flow-resistive properties of the pulmonary vasculature. This approach forces one to make assumptions about the vascular effects of the drug on the basis of single pressure-flow measurements before and during therapy. When these data are used to define a "resistance," as derived from Poiseuille's law, it is implied that the relationship between pressure and flow in the pulmonary circulation is linear, and that flow begins (zone III) when the upstream pressure (PAP) exceeds the apparent downstream left atrial or left ventricular end-diastolic pressure (LVEDP).i 6 To fully describe the pressure-flow relationship of the pulmonary vasculature, determinations of pressure-flow coordinates would have to be made at several levels of CO. With such multicoordinate lines, many investigators have demonstrated that at physiologic rates of flow in isolated lobe or lung preparations, the PAP-flow relationship can indeed be described by a linear relationship.5' 7-10 However, the pressure intercept, obtained by linear extrapolation of the pressure-flow line to zero flow, has been reported to exceed the apparent downstream pressure.7`9 This extrapolated pressure intercept may represent the mean outflow or closing pressure of the lung vasculature. 6 7 The slope of the pressure-flow line defines the incremental pulmonary vascular resistance.5'6 Although one can always calculate a resistance using the conventional equation, it may provide little insight into pathophysiologic mechanisms, and may in fact be misleading in comparisons of conditions in which CO and/or closing pressure have been altered.
This study investigates effects of hydralazine on the pulmonary vascular pressure-flow relationship in a canine preparation of pulmonary hypertension, and demonstrates that hydralazine predominantly affects the mean outflow or closing pressure and not the slope of the pressure-flow relationship.
Methods
Eighteen mongrel dogs (21 to 28 kg) were anesthetized with 30 mg/kg pentobarbital and placed in the supine position. They were intubated and artificially ventilated with a fraction of inspired oxygen (Fio2) of 1, at a tidal volume of 20 ml/kg, and at a rate adjusted to maintain Paco2 between 30 and 40 mm Hg. Two arteriovenous fistulas, composed of a pair of polyethylene catheters (10 cm length, 4 mm inside diameter) joined together by wider bore flexible plastic tubing were inserted bilaterally between the femoral artery and vein of each dog. One fistula was modified with a Y connector to permit the intravenous injection of autologous blood clots. A wide-bore, fluid-filled catheter was introduced into the brachial artery for purposes of blood pressure measurement and arterial blood sampling. A pigtail (No. 8 Cordis) catheter was passed into the left ventricle during pressure monitoring from the opposite brachial artery. Two No. 7F Swan-Ganz catheters were introduced into the external jugular vein: one was advanced into the right ventricle for pressure monitoring, and the other was advanced into the right atrium for injection of saline boluses for determination of CO. A third thermodilution Swan-Ganz catheter was positioned in the proximal pulmonary artery, also for determination of CO (Cardiotherm Computer, Model 500). A minimum of three determinations of CO was obtained. All catheters were connected to Statham P23 ID transducers leveled to the center of the anterior-posterior dimension of the chest at the mid sternum. The outputs from all transducers were displayed on a 12-channel Electronics for Medicine oscillographic recorder. A 200 ml sample of blood was collected in a beaker containing 1000 units of Thrombostat (thrombin USP). The blood was mixed gently and allowed to clot. The clot was later cut into small pieces (less than 1 cm3), yielding approximately 50 ml of clot fragments. The blood removed for the clot was replaced by the intravenous infusion of 6% dextran in saline. A series of measurements of pulmonary pressure-flow coordinates and arterial and mixed venous blood samples could be obtained at baseline and additional levels of CO were produced by means of sequentially opening the fistulas. Hemodynamic measurements were determined from recordings made during a 5 sec breath hold at functional residual capacity.
The sequence of conditions studied in the first 14 dogs was as follows: (1) control before pulmonary embolization, (2) control after pulmonary embolization, and (3) after therapy with hydralazine.
After the series of measurements in the first control period, autologous blood clots were injected via the venous side of the modified arteriovenous fistula. Embolization was carried out over approximately 1 hr. At completion of the embolization, each dog was given heparin (100 units/kg) intravenously to prevent clot propagation. After a subsequent 1 hr stabilization period, the PAP remained stable at two to four times the level before embolization. After the series of measurements in the second control period, hydralazine was given intravenously, initially in 2 to 3 mg aliquots, with the goal of increasing CO by approximately 100%. The maximum drop in blood pressure noted was less than 30%, and the dose of hydralazine required was 10 to 400 mg (excluding the two dogs that required over 300 mg, the mean dosage was 33 + 17 mg).
In the first six dogs (group 1), the series of measurements under each condition consisted of pulmonary vascular pressureflow coordinates and gas exchange at three levels of CO (both arteriovenous fistulas closed, one fistula open, both fistulas open). The PAP and CO always returned to baseline after the fistulas were closed, indicating stability during measurements in each dog. In the next eight dogs (group 2), PAP-flow coordinates in each condition were obtained in a series of five to eight levels of CO by use of variable clamps on the arteriovenous fistulas. In the last four group 2 dogs, a left thoracotomy was initially performed and an inflatable balloon (No. 14 Foley catheter) was inserted into the left atrium via the atrial appendage. Left atrial pressure could be controlled by inflating the balloon and obstructing flow across the mitral valve. After the PAP-flow lines were established in each of the three conditions, the PAP was recorded as the left atrial pressure was sequentially raised. CO was kept constant for each level of left atrial pressure. Accordingly, effects of increasing downstream pressure (left atrial pressure) on upstream pressure (mean PAP) could be determined in each experimental condition. The central lumen of the Foley catheter was used to measure left atrial pressure and this measurement was always within 1 mm Hg of mean pulmonary capillary wedge pressure, when the latter was obtained. The CO was kept from falling as the left atrial pressure was increased by means of partially opening the arteriovenous fistulas and/or a small infusion of dextran.
The group 1 experiments lasted approximately 70 min after the onset of the postemboli studies. The group 2 experiments lasted between 90 (first four dogs) and 120 min (last four dogs). In all dogs the period of time after completion of control 2 to the beginning of hydralazine studies was approximately 35 min. To rule out the possibility that the effects observed after hydralazine were due to time alone, an additional four "time control" dogs were studied without hydralazine. They were prepared in a manner identical to that for the first four group 2 dogs, and 35 min after control 2 measurements a second PAP-CO line was obtained without intervening administration of hydralazine.
Derived hemodynamic parameters were calculated as follows: pulmonary vascular resistance = (PAP -LVEDP)/CO and systemic vascular resistance -(mean blood pressure -RVEDP)/CO, where RVEDP is right ventricular end-diastolic pressure. Intrapulmonary shunt was determined according to the following equation: Qs/Qt = (Cc'02 -CaO2/(Cc'02 -CvO2), where CaO2 = arterial blood 02 content; CvO2 = mixed venous blood 02 content; Cc'02 = end pulmonary capillary blood 02 content. CaO2 and CvO2 were calculated by the formula: (hematocrit/3 x 1.34 x % saturation) + (Po2 x 0.003). Where Po2 was less than 140 mm Hg (i.e., in all mixed venous samples), the % saturation was determined with the nomogram of Rossing and Cainl; otherwise saturation was assumed to be 100%. End capillary blood was assumed to be fully saturated as: Cc'02 = (hematocrit/3 x 1.34 x 100) + (Pbar -Paco2 -47) x Fio2, where Pbar is the barometric pressure. The Fio2 was maintained at 1 throughout the procedure. The percent of dead space ventilation was calculated as (Paco2 -PEco2)/Paco2, where Paco2 = the partial pressure of CO2 in the arterial blood (in mm Hg); PEco2 = the partial pressure of CO2 in the mixed expired air. Blood gas and expired air analysis was performed with a Coming 165/2 PTL blood gas analyzer (Corning Scientific Instruments, Medfield, MA).
For each condition, the effects of altering CO were analyzed by a two-way analysis of variance blocking dogs against level of CO. If a significant F value was obtained at the 5% level of significance, a paired t test was used to compare the mean levels of CO. To compare the effects of different conditions, at the baseline level of CO (fistula closed), a three-way analysis of variance blocking conditions, levels of CO, and dogs was used. If a significant F value was obtained at the 5% level of significance, a paired t test was used to compare the means. Linear regression analysis (least squares method) was performed on PAP-CO curves. An analysis of covariance was then performed between PAP-CO curves to test for differences between slope Vol. 73, No. 5, May 1986 and intercepts at a level of significance of p < .05. All mean results are reported as + SD.
Results
The mean hemodynamic data from group 1 dogs are presented in table 1. Before embolization (control 1), the CO with both fistulas closed (level 1) was 3.4 liters * minm'. Opening the first arteriovenous fistula (level 2) increased CO 26% (p < .01). A similar change in CO occurred when the second fistula was opened (level 3). With each increment in CO, a small but significant increase in mean PAP was produced (both p < .01). Mean arterial pressure tended to drop as the fistulas were opened. There were no significant changes in LVEDP, RVEDP, or pulmonary vascular resistance at the three levels of CO during control 1 measurements. The effects of embolization can be seen by comparing control 1 with control 2 measurements at the first level of CO. There was a marked drop in mean CO (p < .05), and the mean PAP rose to 40.3 mm Hg (p < .0 1). There were no significant alterations in LVEDP or mean arterial pressure after embolization. However, there was a significant increase in mean RVEDP (p < .05) and a marked increase in calculated pulmonary vascular resistance. Pulmonary vascular resistance increased from 1. 1 to 16.5 mm Hg . liter . min-1 (p < .01). In this condition, when the fistulas were opened, the mean PAP again rose significantly at each level of CO (both p < .01). LVEDP did not change when flow increased, and there was a progressive drop noted in the pulmonary vascular resistance.
As per experimental design, hydralazine almost doubled mean CO, from 2.0 to 3.9 liters * min'-(p < .01). Despite the marked increase in flow, no significant change was noted in mean PAP or mean arterial pressure. However, significant decreases in LVEDP, RVEDP, and pulmonary vascular resistance occurred with hydralazine. As the fistulas were sequentially opened, and as illustrated in table 1, there were corresponding increases in CO and PAP. In addition, with each increment in CO, there was a significant decrease in calculated pulmonary vascular resistance.
In each dog a linear regression analysis was performed on the CO-PAP coordinates for each condition. Statistically significant r values were obtained for all 18 of these three-point pressure-flow relationships. The lowest r value was .97, with a p value <.05.
Representative pressure-flow plots are illustrated in figure 1 .
The mean pressure-flow coordinates for group 1 in each condition are plotted in figure 2 . Before embolization, the slope described by the mean coordinates of PAP and CO was 1.4 mm Hg . liter * min-', and the extrapolated pressure intercept was 8. regression analysis). After embolization (control 2) the slope of the pressure-flow relationship increased to 4.6 mm Hg . liter * min-, there was a marked upward shift in the pressure-flow line, and the extrapolated pressure intercept increased to 31.8 mm Hg. After hydralazine there was a parallel downward shift in the pressureflow line so that the extrapolated intercept decreased by 25% to 24.0 mm Hg. The effects of embolization on gas exchange are summarized in table 2. The Po2 did not significantly change between the different conditions. Intrapulmonary shunt (with Fio2 = 1) was not altered by embolization, although during hydralazine therapy it increased (p < .01). Embolization increased dead space ventilation and hydralazine caused a significant decrease in this parameter.
The eight group 2 dogs had multicoordinate pressure-flow lines under the three conditions. The hemodynamic data obtained in each dog with both fistulas closed are presented in table 3. These changes were similar to those observed in the group 1 dogs, as presented in table 1. In table 4, the individual values for regression coefficient, slope, and intercept of each pressure-flow line are presented for each of the three conditions, with the corresponding LVEDP. For each dog the LVEDP varied by less than 2 mm Hg during the series of measurements under each condition. As seen in the group 1 dogs, a marked increase in the extrapolated pressure intercept of each pressure-flow line was produced by embolization (mean change from 8.8 to 28.6 mm Hg). Analysis of covariance revealed that in each dog, the increase in the pressure intercept was highly statistically significant. There was also a moderate increase in the slope of each pressure-flow relationship, from 1.8 to 3.5 mm Hg * liter min1; this was only statistically significant in six of the eight dogs. In every dog hydralazine therapy resulted in a significant decrease in extrapolated pressure intercept (mean change 23%) almost identical to that seen in the analysis of mean coordinates in the group 1 dogs. In every dog hydralazine also had a tendency to decrease the slope of each individual pressure-flow line. However, this was only significant in five of eight dogs. Note that before embolization, the LVEDP was less than the extrapolated pressure intercept in every dog ,except one. The subsequent changes in LVEDP under the other two conditions could not explain the changes in extrapolated intercept in any dog. The slopes, intercepts, and LVEDP from the four time control dogs are presented in table 5. Over a similar time period as that between control 2 and posthydralazine measurements (table 4), only small and inconsistent changes in slope or extrapolated pressure intercept were observed.
The individual pressure-flow plots in the last four group 2 dogs are presented in figure 3 . For each dog, the corresponding relationship of left atrial pressure to PAP at constant CO is also presented for each condition. Before embolization, as left atrial pressure was progressively increased via balloon inflation, a nearly one for one increment in PAP was observed. After embolization, increments in left atrial pressure had trivial effects on PAP.
Discussion
Characterization of the pulmonary vascular pressure-flow relationship in normal, isolated lungs or lobes has been performed by several investigators.5' -10 Over physiologic rates of flow, the relationship is well described by a linear model and thus may reflect a constant vascular cross-sectional area for flow. Graham et al. 7 and Shoukas9 have demonstrated, in isolated lungs, that at lower, nonphysiologic rates of flow the relationship becomes curvilinear convex to the pressure axis; this finding is probably explained by vascular derecruitment.5 Therefore, extrapolation of the linear portion of the pressure-flow curve to zero flow does not describe the pressure-flow relationship at low flow tates, but rather may indicate the effective downstream or outflow pressure that is operative in the lungs at physiologic rates of flow.6 7 If the left atrial pressure is sufficiently high, it will be the highest downsteam pressure and the pressure-flow line should intersect the pressure axis at this pressure. For example, Shoukas9 has reported, in isolated canine lungs with fixed airway pressure of 5 mm Hg, that as pulmonary venous pressure is raised from 2 to 8 mm Hg, the pressure intercept begins to approximate the pulmonary venous pressure. Conversely, at a low pulmonary venous pressure (<0 cm H20) and a higher airway TABLE 4 Effects of emboli and hydralazine on the slope and intercept of the pulmonary pressure-flow curve in group 2 pressure (5 cm H120), Graham et al. 7 have demonstrated that the pressure intercept is greater than either value alone. In this situation the vascular closing pressure is the dominant downstream pressure as represented by the pressure intercept.
In the current experiment, multiple pulmonary emboli caused marked pulmonary hypertension. This increase in mean PAP was produced despite a lower cardiac output, and without significant change in the apparent downstream pressure (left atrial or LVEDP). Standard calculation of the pulmonary vascular resistance after embolization suggests a marked decrease in vascular cross-sectional area and an increase in the flow-resistive properties of the pulmonary vasculature. On the other hand, examination of the pressure-flow plots (figures 1 to 3) suggests that the predominant reason for the increase in mean PAP induced by embolization is not an increase in the slope of the pressureflow line, but is related to a marked increase in the extrapolated pressure intercept (increased vascular closing pressure). As seen in the group 2 dogs, in which multiple pressure-flow coordinates were obtained, a highly significant increase in pressure intercept was seen in each dog. To test the hypothesis that the extrapolated pressure intercept reflects the effective downstream or outflow pressure, we progressively raised left atrial pressure at a constant CO. Before embolization, increases in left atrial pressure over a given range (approximately 8 to 17 mm Hg; see figure  3 ) caused similar changes in PAP, indicating that left atrial pressure approximated the effective outflow pressure. In contrast, after embolization, changes in left atrial pressure over the same range had only trivial effects on PAP. Note that after embolization even large increases in left atrial pressure failed to cause equivalent changes in PAP. Accordingly, as signaled by the change in extrapolated pressure intercept, embolization resulted in a marked increase in the effective outflow pressure.
Hydralazine had profound effects on CO and produced a marked fall in the calculated pulmonary vascular resistance (see table 1 ). However, the pressureflow relationship after hydralazine indicates that the predominant effect was to cause downward displacement of the pressure-flow curve to a lower pressure intercept, i.e., to decrease the effective outflow pressure (figures 2 and 3 ). In the group 2 dogs in which multicoordinate pressure-flow lines were obtained, the slope significantly fell in five of eight dogs. This tendency for slope to decrease probably indicates some increase in the vascular cross-sectional area after hydralazine. This contention is supported by a significant decrease in dead space ventilation. Hydralazine must have reestablished blood flow to alveolar capillaries that had closed after embolization. Furthermore, it is possible that the increase in the intrapulmonary shunt with hydralazine may indicate the opening of previously nonperfused shunt units.
Because of the long half-life of hydralazine, it would have been impossible to obtain time control measurements after its administration in this setting.
However, the hemodynamic effects of hydralazine observed by us were similar to those observed in previous canine and human studies of pulmonary hypertension. Furthermore, in the four time control dogs (table 5) no consistent effects of time on the PA-CO plots were observed. Therefore, we do not believe that time alone produced the effects seen with the drug. Shoukas et al. 10 have reported that large changes in carotid sinus pressure may produce small shifts in the pulmonary vascular pressure-flow relationship. The changes in blood pressure that we observed after opening the fistulas in each condition or after hydralazine therapy were small, and would not be expected to have altered the PA-CO plots.
We are uncertain of the precise mechanism involved in the production of pulmonary hypertension in this canine preparation. In addition to fixed mechanical obstruction of vascular units by clot fragments as indicated by increased incremental resistance, humoral'2 or other reflex mechanisms13 may contribute to the shift in the pulmonary vascular pressure-flow relationship by increasing tone at collapsible vascular sites. Hydralazine, through its action on vascular muscle, was able to partially reverse this effect. Since intrapulmonary shunting did not develop after pulmonary embolization, it is unlikely that the shift in pressure-flow relationship was produced by alveolar edema. The lack of change in the intrapulmonary shunt does not rule out the possibility that interstitial edema was produced by embolization, with a subsequent increase in interstitial pressure affecting the PA-CO relationship. We did not measure lung compliance, which may have indicated the appearance of interstitial edema. However, data from Levy and Simmonsl4 indicate that lung compliance is unaffected in heparinized dogs, in which the intrapulmonary shunt does not increase after autologous clot embolization.
Hydralazine has been reported to decrease pulmonary vascular resistance and improve ventricular performance in patients with primary and secondary pulmonary hypertension.'-3 This decrease in pulmonary vascular resistance has been attributed to an increase in vascular cross-sectional area. Alternatively, findings in this canine preparation suggest that hydralazine predominantly causes a significant decrease in the pulmonary vascular closing pressure.
